Sigmund, Audrey M.
Huang, Ying
Ruppert, Amy S. http://orcid.org/0000-0001-9612-6473
Maddocks, Kami
Rogers, Kerry A.
Jaglowski, Samantha http://orcid.org/0000-0002-4335-2554
Bhat, Seema A.
Kittai, Adam S.
Grever, Michael R.
Byrd, John C.
Woyach, Jennifer A. http://orcid.org/0000-0002-3403-9144
Article History
Received: 25 February 2022
Revised: 29 April 2022
Accepted: 28 June 2022
First Online: 16 July 2022
Competing interests
: KM has consulted with Acerta, AstraZeneca, Pharmacyclics, Beigene, Loxo, Lilly, Genentech, Morphosys, Celgene, BMS, Kite. KAR received research funding from Genentech, AbbVie, and Janssen, consulted for Acerta Pharma, AstraZeneca, Innate Pharma, AbbVie, Genentech, Pharmacyclics, and Beigene, and received travel funding from AstraZeneca. SJ has consulted for Kite, Novartis, Juno, Takeda, CRISPR Therapeutics and has received research funding from Kite, Novartis, Juno, Caribou. ASK has consulted for Abbvie, Beigene, Bristol-Myers Squibb, and Janssen. MRG has received consult funding from Pharmacyclics, Astra Zeneca, Ascerta and Axio. JCB has consulted with Acerta, AstraZeneca, Pharmacyclics, Astellas, Syndax, and Jazz Pharmaceuticals and has stock ownership in Vincerx Pharmaceutics. JAW has consulted with Abbvie, AstraZeneca, Beigene, Janssen, Pharmacyclics, Loxo, and Newave, receives research funding from Morphosys, Karyopharm, Pharmacyclics, Janssen, and Schrodinger.